{"meta":{"status":200,"messages":[],"pagination":{"max":1,"offset":0,"count":1,"total":1,"pageNum":1,"totalPages":1,"sort":null,"currentUrl":"https://api.digitalmedia.hhs.gov/api/v2/resources/media.json?offset=0&max=1&ignoreHiddenMedia=1&format=json&id=1107&newUrlBase=http://www.cdc.gov/flu/protect/vaccine","nextUrl":null,"previousUrl":null}},"results":[{"content":"\n
\n

Influenza vaccines \u2014 United States, 2018\u201319 influenza season*

\n
\n
\n
\n
\n

Back to Seasonal Influenza Vaccination Resources for Health Professionals

\n
\n
\n
\n
\n
\n
\n

U.S. Influenza Vaccine Products for the 2018-19 Season

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n

Inactivated Influenza Vaccines (IIVs) and Recombinant Influenza Vaccine (RIV4)

\n
Trade Name [Manufacturer] Presentation Age Indication HA, \u00b5G/dose (each virus) Egg-grown virus, Cell culture-grown virus, or Recombinant HAAdjuvanted Yes/NoLatex Yes/NoThimerosal Yes/No
If yes, Mercury,
?g/0.5mL
Quadrivalent IIVs (IIV4s)
Afluria Quadrivalent* Seqirus 0.5 mL prefilled syringe?3 yrs15EggNoNoNo
5.0 mL multi-dose vial?6 mos (needle/syringe)

18 through 64 yrs (jet injector)

 7.5/0.25* mL

15/0.5 mL

EggNoNoYes (24.5)
Fluarix Quadrivalent GlaxoSmithKline 0.5 mL prefilled syringe?6 months15EggNoNoNo
FluLaval Quadrivalent ID Biomedical Corp. of Quebec 0.5 mL prefilled syringe?6 months15EggNoNoNo
5.0 mL multi-dose vial?6 months 15EggNoNoYes (<25)
Flucelvax Quadrivalent Seqirus (ccIIV4)0.5 mL prefilled syringe?4 yrs15CellNoNoNo
5.0 mL multi-dose vial?4 yrs 15CellNoNoYes (25)
Fluzone Quadrivalent* Sanofi Pasteur 0.25 mL prefilled syringe6 through 35 months7.5/0.25 mLEggNoNoNo
0.5 mL prefilled syringe?6 months15/0.5 mL EggNoNoNo
0.5 mL single-dose vial ?6 months  15/0.5 mL Egg NoNoNo
5.0 mL multi-dose vial?6 months7.5/0.25* mL

15/0.5 mL

 Egg NoNoYes (25)
Trivalent IIV (IIV3s)
Afluria*
Seqirus 		0.5 mL prefilled syringe?3 yrs15EggNoNoNo
5.0 mL multi-dose vial?6 mos (needle/syringe)

18 through 64 yrs (jet injector)

 7.5/0.25* mL

15/0.5 mL

Egg NoNoYes (24.5)
Fluad
Seqirus (aIIV3)		0.5 mL prefilled syringe?65 yrs15EggYesNoNo
Fluzone High-Dose Sanofi Pasteur (HD-IIV3)0.5 mL prefilled syringe?65 yrs60EggNoNoNo
Quadrivalent RIV (RIV4)
Flublok Quadrivalent Sanofi Pasteur 0.5 mL prefilled syringe?18 yrs45RecombinantNoNoNo
\n

Abbreviations: IIV=inactivated influenza vaccine; RIV=recombinant influenza vaccine; HA=hemagglutinin; mos=months; yrs=years.

\n

* For Afluria and Afluria Quadrivalent, the dose volume for children aged 6 through 35 months is 0.25mL.  For Fluzone Quadrivalent, children aged 6 through 35 months may receive either 0.25mL or 0.5mL.

\n
\n
\n
\n
\n
\n
\n
\n
\n

Administration of IIVs and RIV4

\n
    \n
  • IIVs and RIV4 are administered intramuscularly (IM): \n
      \n
    • Adults and older children: the deltoid is the preferred site;
      • \n
    • Infants and younger children (IIVs only): the anterolateral thigh is the preferred site.
      • \n
    • Detailed guidance for administration sites and needle length is available in Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP)
      • \n
    • Afluria and Afluria Quadrivalent are licensed for intramuscular administration via jet injector (the Pharmajet Stratis), for persons aged 18-64 years only.
      • \n
    • RIV4 is licensed for persons aged ?18 years
      • \n
    • \n
\n

IIV and RIV4 Contraindications and Precautions

\n

Contraindications:

\n
    \n
  • History of severe allergic reaction to the vaccine or any of its components \n
      \n
    • ACIP recommends that persons with egg allergy of any severity receive influenza vaccine (see Persons with a History of Egg Allergy, above)
      • \n
    • Information about vaccine components is located in package inserts from each manufacturer.
      • \n
    • \n
\n

Precautions:

\n
    \n
  • Moderate or severe acute illness with or without fever.
    • \n
  • Guillain\u2013Barr\u00e9 syndrome within 6 weeks following a previous dose of influenza vaccine.
    • \n
\n
\n
\n
\n
\n
\n
\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n

Live Attenuated Influenza Vaccine (LAIV4)

\n
Trade Name ManufacturerPresentationAge IndicationVirus Dose
per 0.2mL
(each virus)		Egg-grown virus, Cell
culture-grown virus,
or Recombinant HA		Adjuvanted
(Yes/No)		Latex
(Yes/No)		Thimerosal
Yes/No
If yes, Mercury,
?g/0.5mL
FluMist Quadrivalent
AstraZeneca 		0.2 prefilled
intranasal sprayer		2 through 49 yrs106.5\u20137.5
fluorescent
focus units		EggNoNoNo
\n

Abbreviations: LAIV=live attenuated influenza vaccine; mos=months; yrs=years.

\n
\n
\n
\n
\n
\n
\n
\n
\n

LAIV4 Administration

\n
    \n
  • LAIV is administered intranasally using the supplied prefilled, single-use sprayer containing 0.2 mL of vaccine. \n
      \n
    • Half of the total sprayer contents is sprayed into the first nostril while the recipient is in the upright position.
      • \n
    • The attached divider clip is removed and the second half of the dose administered into the other nostril.
      • \n
    • \n
  • If the vaccine recipient sneezes immediately after administration, the dose should not be repeated.
    • \n
  • If nasal congestion impedes delivery of the vaccine to the nasopharyngeal mucosa, deferral should be considered, or another age appropriate vaccine should be administered.
    • \n
\n

LAIV4 Contraindications and Precautions

\n

\n

Contraindications:

\n
    \n
  • History of severe allergic reaction to any vaccine component or after previous dose of any influenza vaccine; \n
      \n
    • ACIP recommends that persons with egg allergy of any severity receive influenza vaccine (see Persons with a History of Egg Allergy, above)
      • \n
    • Information about vaccine components is located in package inserts from the manufacturer.
      • \n
    • \n
  • Concomitant aspirin or salicylate-containing therapy in children and adolescents;
    • \n
  • Children aged 2 through 4 years who have received a diagnosis of asthma or whose parents or caregivers report that a health care provider has told them during the preceding 12 months that their child had wheezing or asthma or whose medical record indicates a wheezing episode has occurred during the preceding 12 months;
    • \n
  • Children and adults who are immunocompromised due to any cause (including immunosuppression caused by medications or by HIV infection);
    • \n
  • Close contacts and caregivers of severely immunosuppressed persons who require a protected environment;
    • \n
  • Pregnancy;
    • \n
  • Receipt of influenza antiviral medication within previous 48 hours.
    • \n
\n

Precautions:

\n
    \n
  • Moderate or severe acute illness with or without fever;
    • \n
  • History of Guillain-Barr\u00e9 syndrome within 6 weeks of receipt of influenza vaccine;
    • \n
  • Asthma in persons aged ?5 years;
    • \n
  • Other underlying medical conditions that might predispose to complications attributable to severe influenza (e.g., chronic pulmonary, cardiovascular [excluding isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)).
    • \n
\n
\n
\n
\n
\n
\n
\n
\n

Vaccine Abbreviations

\n
\n
    \n
  • IIV = Inactivated Influenza Vaccine. \n
      \n
    • IIV3 = Trivalent Inactivated Influenza Vaccine;
      • \n
    • IIV4 = Quadrivalent Inactivated Influenza Vaccine.
      • \n
    • \n
  • RIV4 = Quadrivalent Recombinant Influenza Vaccine.
    • \n
  • LAIV4 = Quadrivalent Live Attenuated Influenza Vaccine
    • \n
  • aIIV3 refers specifically to adjuvanted IIV3
    • \n
  • ccIIV4 refers specifically to cell-culture based IIV4
    • \n
  • HD-IIV3 refers specifically to high-dose IIV3
    • \n
  • SD-IIV3 and SD-IIV4 refer specifically to standard-dose IIVs
    • \n
\n
\n
\n \n  Top of Page \n
\n
\n
\n \n
Syndicated Content Details:
Source URL: http://www.cdc.gov/flu/protect/vaccine/vaccines.htm
Source Agency: Centers for Disease Control and Prevention (CDC)
Captured Date: 2014-04-26 00:40:05.0
","description":"A chart of recommended available 2014-15 influenza vaccines by type and manufacturer - CDC","id":1107,"mediaType":"Html","name":"Influenza Vaccines - United States, 2014-15 Influenza Season","sourceUrl":"http://www.cdc.gov/flu/protect/vaccine/vaccines.htm"}]}